002675 东诚药业
已收盘 08-12 15:00:00
资讯
新帖
简况
东诚药业（002675）披露控股股东部分股权质押展期公告，8月12日股价下跌0.22%
证券之星 · 08-12 22:39
东诚药业（002675）披露控股股东部分股权质押展期公告，8月12日股价下跌0.22%
东诚药业(002675.SZ)：原料药贝米肝素钠上市申请获受理
智通财经 · 08-06
东诚药业(002675.SZ)：原料药贝米肝素钠上市申请获受理
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
证券之星 · 08-06
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
东诚药业（002675）披露回购公司股份进展情况公告，8月4日股价下跌0.46%
证券之星 · 08-04
东诚药业（002675）披露回购公司股份进展情况公告，8月4日股价下跌0.46%
股市必读：东诚药业新发布《关于公司原料药产品取得德国汉堡卫生当局颁发的GMP证书的公告》
证券之星 · 08-03
股市必读：东诚药业新发布《关于公司原料药产品取得德国汉堡卫生当局颁发的GMP证书的公告》
东诚药业最新公告：原料药产品获德国汉堡卫生当局GMP证书
证券之星 · 07-31
东诚药业最新公告：原料药产品获德国汉堡卫生当局GMP证书
东诚药业（002675）披露控股股东部分股权展期及补充质押公告，7月27日股价上涨2.26%
证券之星 · 07-27
东诚药业（002675）披露控股股东部分股权展期及补充质押公告，7月27日股价上涨2.26%
新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？
智通财经 · 07-25
新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？
东诚药业：177Lu-LNC1011为前列腺癌治疗核素药物
证券之星 · 07-07
东诚药业：177Lu-LNC1011为前列腺癌治疗核素药物
东诚药业（002675）披露回购公司股份进展情况公告，7月1日股价上涨1.83%
证券之星 · 07-01
东诚药业（002675）披露回购公司股份进展情况公告，7月1日股价上涨1.83%
东诚药业：18F-LNC1001思睿肽注射液目前正在审核中
证券之星 · 07-01
东诚药业：18F-LNC1001思睿肽注射液目前正在审核中
东诚药业（002675）披露为合营公司提供8000万元担保进展，6月30日股价下跌1.49%
证券之星 · 06-30
东诚药业（002675）披露为合营公司提供8000万元担保进展，6月30日股价下跌1.49%
股市必读：东诚药业（002675）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：东诚药业（002675）6月18日董秘有最新回复
东诚药业最新公告：子公司蓝纳成重新递交H股上市申请
证券之星 · 06-15
东诚药业最新公告：子公司蓝纳成重新递交H股上市申请
东诚药业(002675.SZ)：吉林长春核药生产中心投入运营
智通财经 · 06-15
东诚药业(002675.SZ)：吉林长春核药生产中心投入运营
蓝纳成冲刺港股：年亏1.5亿 东诚药业是大股东
雷递网 · 06-14
蓝纳成冲刺港股：年亏1.5亿 东诚药业是大股东
东诚药业：氟[18F]思睿肽注射液不符合医保目录预申报条件
证券之星 · 06-09
东诚药业：氟[18F]思睿肽注射液不符合医保目录预申报条件
东诚药业：齐康原的回旋加速器项目尚未正式投产
证券之星 · 06-03
东诚药业：齐康原的回旋加速器项目尚未正式投产
东诚药业：公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份
证券之星 · 06-03
东诚药业：公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份
东诚药业（002675）披露为全资子公司提供3亿元担保公告，6月2日股价下跌0.39%
证券之星 · 06-02
东诚药业（002675）披露为全资子公司提供3亿元担保公告，6月2日股价下跌0.39%
加载更多
公司概况
公司名称：
烟台东诚药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-05-25
主营业务：
烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。
发行价格：
26.00
{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":13.31,"timestamp":1786518189000,"preClose":13.34,"halted":0,"volume":9455204,"delay":0,"changeRate":-0.0022,"floatShares":743000000,"shares":825000000,"eps":0.2478,"marketStatus":"已收盘","change":-0.03,"latestTime":"08-12 15:00:00","open":13.36,"high":13.51,"low":13.25,"amount":127000000,"amplitude":0.0195,"askPrice":13.31,"askSize":33,"bidPrice":13.3,"bidSize":468,"shortable":0,"etf":0,"ttmEps":0.2478,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786584600000},"marketStatusCode":5,"adr":0,"adjPreClose":13.34,"symbolType":"stock","openAndCloseTimeList":[[1786498200000,1786505400000],[1786510800000,1786518000000]],"highLimit":14.67,"lowLimit":12.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.57,"roa":"--","peRate":53.712672,"roe":"0.77%","epsLYR":0.2372,"committee":0.43373,"marketValue":10975000000,"turnoverRate":0.0127,"status":1,"floatMarketCap":9894000000},"requestUrl":"/m/hq/s/002675","defaultTab":"news","newsList":[{"id":"2658167905","title":"东诚药业（002675）披露控股股东部分股权质押展期公告，8月12日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658167905","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658167905?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:39","pubTimestamp":1786545555,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，东诚药业报收于13.31元，较前一交易日下跌0.22%，最新总市值为109.75亿元。该股当日开盘13.36元，最高13.51元，最低13.25元，成交额达1.27亿元，换手率为1.27%。近日，东诚药业披露《关于控股股东部分股权质押展期的公告》。公告显示，公司控股股东烟台东益生物工程有限公司将其持有的部分股权进行质押展期，合计质押22,000,000股，占其所持股份比例17.62%，占公司总股本比例2.67%。公司控股股东及其一致行动人资信状况良好，具备相应资金偿还能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657114631","title":"东诚药业(002675.SZ)：原料药贝米肝素钠上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657114631","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657114631?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:41","pubTimestamp":1786020083,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的关于原料药贝米肝素钠上市申请的《受理通知书》。贝米肝素钠为一种低分子量肝素，其制剂为贝米肝素钠注射液，适用于血液透析时预防体外循环中发生凝血、预防普外手术和骨科手术患者的血栓栓塞性疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657830524","title":"股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657830524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657830524?lang=zh_cn&edition=full","pubTime":"2026-08-06 02:00","pubTimestamp":1785952850,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，东诚药业报收于12.84元，下跌0.39%，换手率0.72%，成交量5.38万手，成交额6895.65万元。当日关注点交易信息汇总：8月5日主力资金净流出236.91万元，占总成交额3.44%。公司公告汇总：截至7月31日，东诚药业已回购股份7,399,499股，占总股本0.90%，支付资金总额100,168,758.70元，回购用途为股权激励和/或员工持股计划。本次回购符合相关法律法规及公司既定方案。公司未在禁止期间回购股票，委托价格和交易时段均符合监管要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552045","title":"东诚药业（002675）披露回购公司股份进展情况公告，8月4日股价下跌0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552045?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:46","pubTimestamp":1785854775,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，东诚药业报收于12.89元，较前一交易日下跌0.46%，最新总市值为106.29亿元。该股当日开盘12.99元，最高13.14元，最低12.86元，成交额达8419.96万元，换手率为0.87%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。本次回购符合相关法律法规及公司既定方案。公司未在禁止期间回购股票，委托价格和交易时段均符合监管要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343847","title":"股市必读：东诚药业新发布《关于公司原料药产品取得德国汉堡卫生当局颁发的GMP证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343847","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343847?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:20","pubTimestamp":1785694823,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，东诚药业报收于12.82元，上涨0.23%，换手率0.9%，成交量6.67万手，成交额8562.59万元。当日关注点交易信息汇总：7月31日主力资金净流出375.84万元，占总成交额4.39%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FDXMmain","FDAXmain","FDXSmain","002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655551364","title":"东诚药业最新公告：原料药产品获德国汉堡卫生当局GMP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2655551364","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655551364?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:40","pubTimestamp":1785505257,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司近日收到德国汉堡卫生当局颁发的肝素钠原料药、依诺肝素钠原料药、那屈肝素钙原料药和硫酸软骨素钠原料药GMP证书，有效期三年。此次认证标志着上述产品可继续在欧盟市场销售，为公司原料药海外市场拓展提供保障。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100040437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239","FDXMmain","FDXSmain","FDAXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654504644","title":"东诚药业（002675）披露控股股东部分股权展期及补充质押公告，7月27日股价上涨2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654504644","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654504644?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:47","pubTimestamp":1785163632,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，东诚药业报收于12.67元，较前一交易日上涨2.26%，最新总市值为104.48亿元。该股当日开盘12.4元，最高12.73元，最低12.35元，成交额达1.04亿元，换手率为1.11%。公告显示，公司控股股东烟台东益生物工程有限公司将其持有的部分公司股权进行展期及补充质押。截至公告日，东益生物累计质押41,410,000股，占其所持股份的33.16%。公司控股股东及其一致行动人资信状况良好，具备资金偿还能力，目前不存在平仓风险，不会导致实际控制权变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700035244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654205506","title":"新股前瞻|核药产业爆发前夜，蓝纳成能否成为千亿赛道先行者？","url":"https://stock-news.laohu8.com/highlight/detail?id=2654205506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654205506?lang=zh_cn&edition=full","pubTime":"2026-07-25 13:55","pubTimestamp":1784958933,"startTime":"0","endTime":"0","summary":"截至目前，公司多款核心产品已推进至临床后期，具备显著的先发优势。18F-LNC1005是另一款靶向FAP的候选诊断放射性药物，用于胃癌患者的PET影像。目前该药物已向NMPA提交III期前咨询会议申请，预期于2026年第四季度启动III期阶段，并于2027年完成。而本次东诚分拆上市的蓝纳成，目前仍处于研发投入期，亏损持续扩大。资产负债方面，截至2025年末公司流动资产2.64亿万元，流动负债6854.3万元，现金及等价物为2.57亿元。目前，蓝纳成已在山东烟台建成4886平方","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","IBBQ","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649677478","title":"东诚药业：177Lu-LNC1011为前列腺癌治疗核素药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2649677478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649677478?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:27","pubTimestamp":1783384023,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业07月06日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，看到贵司的1001，CDE审评排位116位，是不是快获批了？前列癌治疗药物1011，本次 递交招股书比上次递交招股书的进展快了很多，临床数据怎么样？本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700006867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648508544","title":"东诚药业（002675）披露回购公司股份进展情况公告，7月1日股价上涨1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648508544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648508544?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:59","pubTimestamp":1782917949,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，东诚药业报收于12.78元，较前一交易日上涨1.83%，最新总市值为105.38亿元。该股当日开盘12.53元，最高12.83元，最低12.35元，成交额达1.28亿元，换手率为1.36%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。公告指出，回购符合相关法规及公司既定方案，公司未在禁止回购期间进行操作，委托价格及时段均符合监管要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648015543","title":"东诚药业：18F-LNC1001思睿肽注射液目前正在审核中","url":"https://stock-news.laohu8.com/highlight/detail?id=2648015543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648015543?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:53","pubTimestamp":1782910396,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：1、18F-LNC-1001思睿肽注射液，有可能中国最早上市的前列腺癌核素诊断药物，CDE官网审评进度116位，请问目前是什么状态？东诚药业回复：您好，1、18F-LNC1001思睿肽注射液前期已提交上市申请，并于2026年1月9日获得CDE受理，目前正在审核中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100041224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647345215","title":"东诚药业（002675）披露为合营公司提供8000万元担保进展，6月30日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647345215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647345215?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:53","pubTimestamp":1782813198,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，东诚药业报收于12.55元，较前一交易日下跌1.49%，最新总市值为103.49亿元。近日，东诚药业发布《关于为合营公司提供担保的进展公告》。齐康原股东EZ按其持有的50%股权向公司提供4,000万元反担保。公司已于2026年3月25日和4月15日通过董事会及股东会审议，同意2026年度为齐康原提供不超过38,000万元担保额度。截至公告日，公司实际对外担保余额为117,800万元，占2025年经审计净资产的27.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000033587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645019860","title":"股市必读：东诚药业（002675）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645019860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645019860?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:37","pubTimestamp":1782077831,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，东诚药业报收于12.72元，上涨0.32%，换手率0.84%，成交量6.23万手，成交额7938.55万元。董秘最新回复投资者： 你好，贵公司子公司蓝纳成港股上市证监会备案审理用时已经260天，在备案历史时间来说已经算是很长的，请问目前备案遇到什么障碍了吗？投资者： 董秘您好，请问截至2026年6月11日收盘，公司最新的股东人数是多少？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203602","title":"东诚药业最新公告：子公司蓝纳成重新递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643203602?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:00","pubTimestamp":1781524842,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司所属子公司烟台蓝纳成生物技术股份有限公司于2026年6月12日向香港联交所重新递交H股发行上市申请，并刊发申请资料。该申请为草拟版本，可能适时更新。本次发行尚需取得证监会、香港证监会及香港联交所等监管机构的备案或批准，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500030033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643279784","title":"东诚药业(002675.SZ)：吉林长春核药生产中心投入运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2643279784","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643279784?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:58","pubTimestamp":1781513926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，近日，公司收到全资子公司南京江原安迪科正电子研究发展有限公司(以下简称“安迪科”)的通知，通知其收到江苏省药品监督管理局下发的《放射性药品生产许可证》，新增吉林长春核药生产中心。此次审查的通过标志着安迪科的吉林长春核药生产中心已达到投产要求，安迪科将新增一个核药生产中心。核药生产中心投产后，将有利于安迪科开拓市场、提升销售收入，进一步完善全国核药网络化建设布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643245815","title":"蓝纳成冲刺港股：年亏1.5亿 东诚药业是大股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2643245815","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643245815?lang=zh_cn&edition=full","pubTime":"2026-06-14 12:55","pubTimestamp":1781412930,"startTime":"0","endTime":"0","summary":"烟台蓝纳成生物技术股份有限公司（简称：“蓝纳成”）日前更新招股书，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260614/6391703847153512417752524.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260614/6391703847153512417752524.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34024/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4588","BK4585","002675","BK0239","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642945989","title":"东诚药业：氟[18F]思睿肽注射液不符合医保目录预申报条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2642945989","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642945989?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:34","pubTimestamp":1780976042,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)06月08日在投资者关系平台上答复投资者关心的问题。投资者提问：按照最新医保政策，公司的氟[18F]思睿肽注射液是否符合预申报的条件，是否有望搭上2026年的医保申报快车。东诚药业回复：您好，根据最新医保政策，氟[18F]思睿肽注射液不符合医保目录预申报条件。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900015101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640922604","title":"东诚药业：齐康原的回旋加速器项目尚未正式投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2640922604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640922604?lang=zh_cn&edition=full","pubTime":"2026-06-03 08:54","pubTimestamp":1780448050,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司投资的合资公司常州齐康原医疗科技有限公司，医用同位素AC 225正式投产并对外销售了吗？东诚药业回复：您好，齐康原的回旋加速器项目尚未正式投产，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300010055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640636922","title":"东诚药业：公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640636922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640636922?lang=zh_cn&edition=full","pubTime":"2026-06-03 08:46","pubTimestamp":1780447572,"startTime":"0","endTime":"0","summary":"投资者提问：尊敬的懂秘： 在2025年12月份仍知悉贵公司参股南宁中硼联康医疗科技有限公司，但在今年5月份在爱企查中获悉四川中硼联康医疗科技集团有限公司的股东里已经没有贵公司的持股信息！东诚药业回复：您好，公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份，请以国家企业信用信息公示系统为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300009878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911953","title":"东诚药业（002675）披露为全资子公司提供3亿元担保公告，6月2日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640911953?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:46","pubTimestamp":1780393564,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，东诚药业报收于12.73元，较前一交易日下跌0.39%，最新总市值为104.97亿元。近日，东诚药业发布《关于为全资子公司提供担保的进展公告》。公告显示，烟台东诚药业集团股份有限公司与平安银行股份有限公司烟台分行签订《保证担保合同》，为全资子公司南京江原安迪科正电子研究发展有限公司向平安银行申请的30,000万元贷款提供连带责任担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786579908555,"stockEarnings":[{"period":"1week","weight":0.0366},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0464},{"period":"6month","weight":0.0144},{"period":"1year","weight":-0.2174},{"period":"ytd","weight":-0.0255}],"compareEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0084},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0332},{"period":"1year","weight":0.0766},{"period":"ytd","weight":-0.0056}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39547人(较上一季度增加45.95%)","perCapita":"18797股","listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":" 烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}